转移性头颈部鳞癌放疗联合免疫治疗的生存分析
本研究回顾性分析2018年1月至2023年6月94例经根治性治疗后出现远处转移的头颈部鳞癌患者,评估在免疫治疗联合化疗基础上增加转移灶定向放疗(MDRT)能否改善生存。中位总生存期为43.0个月,2年和5年总生存率分别为70.1%和30.1%,转移灶数目和原发肿瘤部位与总生存显著相关。作者认为MDRT联合免疫治疗和化疗可有效改善局部控制和总生存,但需前瞻性临床试验进一步验证。
要点
- 94例转移性头颈部鳞癌患者接受MDRT联合免疫治疗和化疗,中位总生存期43.0个月。
- 2年和5年总生存率分别为70.1%(95%CI 59.7-80.5%)和30.1%(95%CI 11.7-48.5%)。
- 转移灶数目和原发肿瘤部位与总生存显著相关。
核心结论
- 在转移性头颈部鳞癌患者中,MDRT联合免疫治疗和化疗可有效改善局部控制和总生存。
- 作者认为这些发现需通过前瞻性临床试验进一步验证。
研究设计与样本
- 回顾性分析2018年1月至2023年6月94例经根治性治疗后出现远处转移的头颈部鳞癌患者,共164个转移部位。
- 全身治疗方案由多学科团队决定,以程序性细胞死亡蛋白-1(PD-1)抑制剂联合化疗为主要方案。
- 根据转移灶数目和位置采用立体定向体部放疗(SBRT)给予不同剂量。
- 采用Kaplan-Meier法估计生存,Cox回归分析评估临床因素与生存结局的关联。
主要发现
- 最常见原发肿瘤为鼻咽(77.7%),最常见转移部位为肺(46.8%),其次为骨(37.2%)。
- 放疗照射276个转移灶,中位剂量52.3 Gy(范围24-60 Gy)。
- 中位总生存期为43.0个月(范围20.2-65.8)。
- 2年和5年总生存率分别为70.1%(95%CI 59.7-80.5%)和30.1%(95%CI 11.7-48.5%)。
- 单因素和多因素分析显示转移灶数目和原发肿瘤部位与总生存显著相关。
局限性
- 原文为回顾性分析。
- 作者指出这些发现需通过前瞻性临床试验进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Immunotherapy combined with chemotherapy is currently the first-line treatment for metastatic head and neck squamous cell carcinoma (HNSCC). This study aims to evaluate whether adding metastasis-directed radiotherapy (MDRT) to immunotherapy and chemotherapy could improve the survival rate of patients with metastatic HNSCC. MATERIALS AND METHODS: A retrospective analysis was conducted on patients with HNSCC who developed distant metastases after curative treatment. Systemic treatment was determined by the multidisciplinary team, with a programmed cell death-1 (PD-1) inhibitor combined with chemotherapy as the primary approach. The feasibility of radiotherapy was evaluated by clinical and imaging examinations. Stereotactic body radiotherapy (SBRT) was used to deliver different doses according to the number and location of metastatic lesions. Kaplan-Meier method was used to estimate survival, and Cox regression analysis was performed to evaluate the association between clinical factors and survival outcomes. RESULTS: From January 2018 to June 2023, a total of 94 patients with 164 metastatic sites were included for the analysis. The most common primary tumor was the nasopharynx (77.7%), with the lung being the most frequent site of metastasis (46.8%), followed by bone (37.2%). Radiotherapy was administered to 276 metastatic lesions, with a median dose of 52.3 Gy (range: 24-60 Gy). The median overall survival (OS) was 43.0 months (range: 20.2-65.8). The OS rates at 2 and 5 years were 70.1% (95% CI, 59.7-80.5%) and 30.1% (95%CI 11.7-48.5%), respectively. Univariate and multivariate analysis showed that the number of metastases and the location of the primary tumor were significantly associated with OS. CONCLUSIONS: In patients with metastatic HNSCC, MDRT combined with immunotherapy and chemotherapy can effectively improve local control and OS. These findings warrant further validation through prospective clinical trials.
引用
- Xu P, Liu D, Zhou J, et al. Survival analysis of patients with metastatic head and neck squamous cell carcinoma treated with metastasis-directed radiotherapy and immunotherapy. Radiat Oncol. 2025. PMID: 40050916. doi:10.1186/s13014-025-02610-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。